| Literature DB >> 30605678 |
Kai Wang1, Mingfang Liao1, Nan Zhou2, Li Bao1, Ke Ma1, Zhongyong Zheng1, Yujing Wang3, Chang Liu2, Wenzhao Wang1, Jun Wang4, Shuang-Jiang Liu5, Hongwei Liu6.
Abstract
We demonstrated the metabolic benefits of Parabacteroides distasonis (PD) on decreasing weight gain, hyperglycemia, and hepatic steatosis in ob/ob and high-fat diet (HFD)-fed mice. Treatment with live P. distasonis (LPD) dramatically altered the bile acid profile with elevated lithocholic acid (LCA) and ursodeoxycholic acid (UDCA) and increased the level of succinate in the gut. In vitro cultivation of PD demonstrated its capacity to transform bile acids and production of succinate. Succinate supplementation in the diet decreased hyperglycemia in ob/ob mice via the activation of intestinal gluconeogenesis (IGN). Gavage with a mixture of LCA and UDCA reduced hyperlipidemia by activating the FXR pathway and repairing gut barrier integrity. Co-treatment with succinate and LCA/UDCA mirrored the benefits of LPD. The binding target of succinate was identified as fructose-1,6-bisphosphatase, the rate-limiting enzyme in IGN. The succinate and secondary bile acids produced by P. distasonis played key roles in the modulation of host metabolism.Entities:
Keywords: FBPase; Parabacteroides distasonis; bile acids; metabolic disorders; succinate
Mesh:
Substances:
Year: 2019 PMID: 30605678 DOI: 10.1016/j.celrep.2018.12.028
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423